First patient treated in Redwood Pharma Phase II study
Redwood Pharma AB (publ) today announces that the first patient has begun testing of RP101 in a Phase II clinical trial. RP101 is an innovative treatment for chronic dry eye disease in postmenopausal women.Redwood Pharma’s Phase II clinical trial is a randomized and vehicle (placebo) -controlled multicenter study that will be conducted at clinics in Austria, Hungary and Germany. Approximately 100 patients will be each evaluated during a 3-month treatment period. Assuming the trial proceeds according to plan, results should be published no later than Q1 2020. The objectives are to show